Evaluation of renal scars by technetium-labeled dimercaptosuccinic acid scan, intravenous urography, and ultrasonography: a comparative study.

J Pediatr. 120: 399-403Abdelhalim A. Khoury A.E.

Critical appraisal of the top-down approach for vesicoureteral reflux.

Investig Clin Urol. 58: S14-S22

5-year prospective results of dimercapto-succinic acid imaging in children with febrile urinary tract infection: proof that the top-down approach works.

J Urol. 184: 1703-1709

Pediatric radiation exposure and effective dose reduction during voiding cystourethrography.

Radiology. 249: 1002-1009

Availability of (99m)Tc-DMSA.

J Nucl Med. 58: 16NLim R. Bar-Sever Z. Treves S.T.

Is Availability of (99m)Tc-DMSA insufficient to meet clinical needs in the United States? A Survey.

J Nucl Med. 60: 14N-16N

De-duplication of database search results for systematic reviews in EndNote.

J Med Libr Assoc. 104: 240-243

Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms.

Pediatr Nephrol. 26: 1017-1029

Urinary concentration of cytokines in children with acute pyelonephritis.

Eur J Pediatr. 172: 769-774

Interleukin-6 and interleukin-8 levels in the urine of children with renal scarring.

Pediatr Nephrol. 27: 1525-1530

Urine interleukin-6 and interleukin-8 in children with acute pyelonephritis, in relation to DMSA scintigraphy in the acute phase and at 1-year follow-up.

Pediatr Radiol. 24: 513-515

Relationship between serum and urine interleukin-6 elevations and renal scarring in children with acute pyelonephritis.

Scand J Urol Nephrol. 43: 133-137

Urinary levels of interleukin-6 and interleukin-8 in patients with vesicoureteral reflux and renal parenchymal scar.

Pediatr Nephrol. 25: 905-912

The role of serum and urine interleukin-8 on acute pyelonephritis and subsequent renal scarring in children.

Pediatr Infect Dis J. 28: 885-890Yavuz S. Anarat A. Bayazit A.K.

Interleukin-18, CRP and procalcitonin levels in vesicoureteral reflux and reflux nephropathy.

Ren Fail. 35: 1319-1322

Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI.

Pediatrics. 131: 870-879

Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection.

Pediatr Infect Dis J. 22: 438-442

Procalcitonin implication in renal cell apoptosis induced by acute pyelonephritis in children.

Infect Drug Resist. 1: 17-20

Procalcitonin as a predictor of renal scarring in infants and young children.

Pediatr Nephrol. 24: 1199-1204

The role of procalcitonin for acute pyelonephritis and subsequent renal scarring in infants and young children.

J Urol. 186: 2002-2008

Fever duration during treated urinary tract infections and development of permanent renal lesions.

Arch Dis Child. 104: 466-470

Delayed treatment of the first febrile urinary tract infection in early childhood increased the risk of renal scarring.

Acta Paediatr. 106: 149-154Jakobsson B. Berg U. Svensson L.

Renal scarring after acute pyelonephritis.

Arch Dis Child. 70: 111-115

The impact of obesity on febrile urinary tract infection and renal scarring in children with vesicoureteral reflux.

J Pediatr Urol. 13: 67 e1-67 e6

Do serum C-reactive protein and interleukin-6 predict kidney scarring after urinary tract infection?.

Indian J Pediatr. 80: 1002-1006

Renal damage one year after first urinary tract infection: role of dimercaptosuccinic acid scintigraphy.

J Pediatr. 129: 815-820

Correlation of renal ultrasonographic findings with inflammatory volume from dimercaptosuccinic acid renal scans in children with acute pyelonephritis.

J Urol. 173 (): 190-194

Relationship among vesicoureteral reflux, urinary tract infection and renal damage in children.

J Urol. 178 (): 647-651

Comparative efficacies of procalcitonin and conventional inflammatory markers for prediction of renal parenchymal inflammation in pediatric first urinary tract infection.

Urology. 73: 782-786

Association of vesicoureteral reflux and renal scarring in urinary tract infections.

Arch Argent Pediatr. 116: e542-e547

Comparison of procalcitonin and different guidelines for first febrile urinary tract infection in children by imaging.

Pediatr Nephrol. 29: 1567-1574

Serum vitamin A and beta-carotene concentrations and renal scarring in urinary tract infections.

Arch Dis Child. 78: 271-272

Serum soluble ST2 as a marker of renal scar in pediatric upper urinary tract infection.

Cytokine. 120: 258-263

Urinary Biomarkers for Screening for Renal Scarring in Children with Febrile Urinary Tract Infection: Pilot Study.

J Urol. 194: 766-771

Urinary neutrophil gelatinase-associated lipocalin (NGAL) might be an independent marker for anticipating scar formation in children with acute pyelonephritis.

J Ren Inj Prev. 4: 39-44

The diagnosis of febrile urinary tract infection in children may be facilitated by urinary biomarkers.

Pediatr Nephrol. 30: 123-130

Urinary C-megalin for screening of renal scarring in children after febrile urinary tract infection.

Pediatr Res. 83: 662-668

Serum and urine cystatin C levels in children with post-pyelonephritic renal scarring: a pilot study.

Int Urol Nephrol. 39: 1241-1250

Soluble receptors to tumour necrosis factor and interleukin-6 in urine during acute pyelonephritis.

Acta Paediatr. 86: 1198-1202

Interleukin-1 alpha and interleukin-1 receptor antagonist in the urine of children with acute pyelonephritis and relation to renal scarring.

Acta Paediatr. 85: 158-162

Urinary matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 biomarkers for predicting renal scar in children with urinary tract infection.

Turk J Urol. 43: 536-542

Urinary excretion of pentraxin-3 correlates with the presence of renal scar following acute pyelonephritis in children.

Int Urol Nephrol. 51: 571-577

Urine endothelin-1 levels as a predictor of renal scarring in children with urinary tract infections.

Clin Nephrol. 77: 219-224

Urine interleukin-1beta in children with acute pyelonephritis and renal scarring.

Nephrology (Carlton). 12: 487-493

The urinary and serum levels of IL-32 in children with febrile urinary tract infections.

Future Sci OA. 3: FSO242

Urinary C-megalin as a novel biomarker of progression to microalbuminuria: a cohort study based on the diabetes Distress and Care Registry at Tenri (DDCRT 22).

Diabetes Res Clin Pract. 186: 109810

High sensitive C-reactive protein: a new marker for urinary tract infection, VUR and renal scar.

Eur Rev Med Pharmacol Sci. 17: 2598-2604Schoenborn J.R. Wilson C.B.

Regulation of interferon-gamma during innate and adaptive immune responses.

Adv Immunol. 96: 41-101

The role of interleukin-1 in general pathology.

Inflamm Regen. 39: 12

IL-4 in the brain: a cytokine to remember.

J Immunol. 189: 4213-4219

Interleukin-10: new perspectives on an old cytokine.

Immunol Rev. 226: 205-218

The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.

Am J Physiol Renal Physiol. 311: F145-F161

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.

Am J Pathol. 165: 1243-1255

The role of urinary N-Acetyl-beta-d-glucosaminidase in cirrhotic patients with acute kidney injury: multicenter, prospective cohort study.

J Clin Med. 10: 4328

Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology.

Nephrol Dial Transpl. 16: 2442-2443Drucker E. Krapfenbauer K.

Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine.

EPMA J. 4: 7Waerner T. Thurnher D. Krapfenbauer K.

The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine.

EPMA J. 1: 619-626Goh W.W.B. Wang W. Wong L.

Why batch effects matter in omics data, and how to avoid them.

Trends Biotechnol. 35: 498-507Issaq H.J. Waybright T.J. Veenstra T.D.

Cancer biomarker discovery: opportunities and pitfalls in analytical methods.

Electrophoresis. 32: 967-975Simon R.M. Paik S. Hayes D.F.

Use of archived specimens in evaluation of prognostic and predictive biomarkers.

J Natl Cancer Inst. 101: 1446-1452Nygaard V. Rodland E.A. Hovig E.

Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses.

Biostatistics. 17: 29-39

Challenges for environmental epidemiology research: are biomarker concentrations altered by kidney function or urine concentration adjustment?.

J Expo Sci Environ Epidemiol. 26: 1-8Pepe M.S. Li C.I. Feng Z.

Improving the quality of biomarker discovery research: the right samples and enough of them.

Cancer Epidemiol Biomarkers Prev. 24: 944-950

Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.

Clin Chem. 56: 237-243

Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.

Clin Chem. 56: 165-171

Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.

J Proteome Res. 12: 5383-5394

Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research.

J Clin Pathol. 62: 1-5

Biomarker failures.

Clin Chem. 59: 202-204International Human Genome Sequencing, C

Finishing the euchromatic sequence of the human genome.

Nature. 431: 931-945

Metabolomics for investigating physiological and pathophysiological processes.

Physiol Rev. 99: 1819-1875

Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics.

Proteomics. 19: e1700448

Advances in mass spectrometry-based clinical biomarker discovery.

Clin Proteomics. 13: 1Hawkridge A.M. Muddiman D.C.

Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality.

Annu Rev Anal Chem (Palo Alto Calif). 2: 265-277Zou W. She J. Tolstikov V.V.

A comprehensive workflow of mass spectrometry-based untargeted metabolomics in cancer metabolic biomarker discovery using human plasma and urine.

Metabolites. 3: 787-819

After another decade: LC-MS/MS became routine in clinical diagnostics.

Clin Biochem. 82: 2-11Hasin Y. Seldin M. Lusis A.

Multi-omics approaches to disease.

Genome Biol. 18: 83

ELISA in the multiplex era: potentials and pitfalls.

Proteomics Clin Appl. 9: 406-422Pappireddi N. Martin L. Wuhr M.

A review on quantitative multiplexed proteomics.

Chembiochem. 20: 1210-1224Rifai N. Gillette M.A. Carr S.A.

Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Nat Biotechnol. 24: 971-983

Restructuring proteomics through verification.

Biomark Med. 4: 799-803Lopez Puga J. Krzywinski M. Altman N.

Points of significance: Bayes' theorem.

Nat Methods. 12: 277-278Python for the life sciences : a gentle introduction to Python for life scientistsz. Apress, Lancaster, Alexander ; Webster, Gordon. Berkeley, CA